Chiesi Farmaceutici secured exclusive rights to market uniQure's Glybera, the first gene therapy approved in Europe, for treatment of lipoprotein lipase deficiency. Chiesi and uniQure also agreed to jointly develop a hemophilia B gene therapy. UniQure will get 20% to 30% of net royalties on sales of both drugs.

Related Summaries